Unknown

Dataset Information

0

Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial.


ABSTRACT: Introduction: Sequential therapy with vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) is effective in some patients with metastatic renal cell carcinoma (mRCC) progressed from or were intolerant to a prior TKIs. Anlotinib is a multi-kinase inhibitor targeting VEGFR1/2/3, PDGFR and FGFR, which has demonstrated efficacy and safety in first-line treatment of mRCC. This study assessed the potential of anloitnib as second-line treatment for patients with mRCC after prior one VEGFR-TKI. Methods: This is a single-arm, open-label, phase 2 study. Patients progressed after or were intolerant to sorafenib or sunitinib were enrolled. Anlotinib was administrated orally 12 mg once daily for 14 days every 3 weeks. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate (ORR), safety and quality of life (QoL). Results: Forty three patients were enrolled and 42 received anlotinib, of whom 32 progressed after and 10 were intolerant to sorafenib or sunitinib. Median PFS were 14.0 months (95% CI 8.3-20.3) and 8.5 months (95% CI 5.6-16.6) for overall population and patients progressed after a previous VEGFR-TKI, respectively. Median OS was 21.4 months (95% CI 16.0-34.5), confirmed ORR and DCR were 16.7 and 83.3% in overall population. The most common adverse events included diarrhea (47.6%), hypertension (45.2%), hand and foot syndrome (42.9%), and fatigue (40.5%). Grade 3 hematological adverse events occurred in four cases, while no grade 4 hematological adverse events was observed. Conclusions: Anlotinib showed promising efficacy as well as favorable safety as second-line treatment for patients with mRCC. Clinical Trial Registration: www.ClinicalTrials.gov, identifier: NCT02072044.

SUBMITTER: Ma J 

PROVIDER: S-EPMC7221023 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial.

Ma Jianhui J   Song Yan Y   Shou Jianzhong J   Bai Yuxian Y   Li Hanzhong H   Xie Xiaodong X   Luo Hong H   Ren Xiubao X   Liu Jiyan J   Ye Dingwei D   Bai Xianzhong X   Fu Cheng C   Qin Shukui S   Wang Jinwan J   Zhou Ai-Ping AP  

Frontiers in oncology 20200507


<b>Introduction:</b> Sequential therapy with vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) is effective in some patients with metastatic renal cell carcinoma (mRCC) progressed from or were intolerant to a prior TKIs. Anlotinib is a multi-kinase inhibitor targeting VEGFR1/2/3, PDGFR and FGFR, which has demonstrated efficacy and safety in first-line treatment of mRCC. This study assessed the potential of anloitnib as second-line treatment for patients with mRC  ...[more]

Similar Datasets

| S-EPMC5943344 | biostudies-literature
| S-EPMC8176993 | biostudies-literature
| S-EPMC5891194 | biostudies-literature
| S-EPMC3626915 | biostudies-literature
| S-EPMC6276905 | biostudies-literature
| S-EPMC6452312 | biostudies-literature
| S-EPMC5896698 | biostudies-literature
| S-EPMC6429896 | biostudies-literature
| S-EPMC3748004 | biostudies-literature
| S-EPMC5783791 | biostudies-literature